Publications/ References 1) R. Hellweg, U.E. Lang, M. Nagel, A. Baumgartner (2002) Subchronic treatment with lithium increases nerve growth factor content in distinct brain regions of adult rats. Molecular Psychiatry 7: 604-8. 2) U.E. Lang, J. Gallinat, S. Kuhn, R. Hellweg (2002) Nerve Growth Factor and Smoking Cessation. Am J Psychiatry 159: 674-675. 3) S. Waldegger, U. Lang, T. Herzer, H. Suessbrich, K. Binder, A. Lepple-Wienhues, U. Nagl, M. Paulmichl, H.B.G. Franz, L. Kiesl, F. Lang, A. E. Busch (1996) Inhibition of the MinK protein induced K channels in Xenopus oocytes by estrogens. Naunyn Schmiedeberg´s Arch Pharmakol 354: 698-702. 4) U.E. Lang, Piche, E., Juenger, M., Schlattmann, P., Jockers-Scherübl, M.C., Hellweg, R (2002) Nerve growth factor serum levels are not elevated in patients with atopic dermatitis. Dermatology a n d Psychosomatics 3: 30-33. 5) C. Gericke, U.E. Lang, T. Steckler, T. Schulz, R. Hellweg (2003) Nerve Growth Factor content and ChAT activity in different brain regions after excitotoxic lesion of the nucleus magnocellularis in old and young rats. J Neural Transmission 110: 627-39. 6) J. Gallinat, G. Stotz-Ingenlath, U.E. Lang, U. Hegerl (2003). Panic attacks, spike-wave activity, and limbic dysfunction. Pharmacopsychiatry 36: 123-6. 7) S. M. Gold, S. Hartmann, M. Mladek, U.E. Lang, R. Hellweg, R. Reer, M. K. Braumann, K.-H. Schulz, C. Heesen (2003) Basal plasma levels and reactivity of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) to standardized acute exercise in multiple sclerosis and controls. J Neuroimmunol 138: 99-105. 8) U.E. Lang, J. Gallinat, H. Danker-Hopfe, M. Bajbouj, R. Hellweg (2003) Nerve Growth Factor serum concentrations in healthy volunteers: physiological variance and stability. Neurosci Lett 344: 13-6. 9) U.E. Lang, F. Lang, K. Richter, V. Vallon, H.-P. Lipp, J. Schnermann, D. P. Wolfer (2003) Emotional instability but intact spatial cognition in adenosine receptor 1 knock out mice. Behav Brain Research 145: 179-188. 10) M. Bajbouj, J. Gallinat, U.E. Lang, L. Niehaus (2003) Motorcortical excitability after electroconvulsive therapy in patients with major depressive disorder. Suppl Clin Neurophysiol 56: 433-40. 11) M. Jockers-Scherübl, U. Matthies, H. Danker-Hopfe, U.E. Lang, R. Hellweg (2003). Chronic cannabis abuse raises nerve growth factor concentrations in drug-naive schizophrenic patients. J Psychopharmacology 17: 439-45. 12) S. von Richthofen*, U.E. Lang*, R. Hellweg (2003) Effects of stress on NGF content in rat brain. Brain Research 987: 207-213. 13) M. Bajbouj, J. Gallinat; L. Niehaus, U.E. Lang, S. Röricht, B.-U. Meyer (2004) Abnormalities of inhibitory neuronal mechanisms in the motor cortex of patients with schizophrenia. Pharmacopsychiatry 37: 74-80. 14) U.E. Lang, M. Mühlbacher, H. Hesselink, W. Zajaczkowski, W. Danysz, H. Danker-Hopfe, R. Hellweg (2004) No nerve growth factor response to treatment with memantine in adult rats. J Neural Transmission 111: 181-90. 15) U.E. Lang, D. Anders, H. Danker-Hopfe, R. Hellweg (2004) Measurement of Nerve Growth Factor serum concentration in a psychologically stressful situation. Stress 7: 39-42. 16) S. Chourbaji, R. Hellweg, D. Brandis, B. Zörner, C. Zacher, U.E. Lang, F. A. Henn, H. Hörtnagl, P. Gass (2004) Mice with reduced BDNF expression show decreased choline acetyltransferase activity, but regular brain monoamine levels and unaltered emotional behavior. Brain Res Mol Brain Res 121: 28-36. 17) U.E. Lang, R. Hellweg, J. Gallinat (2004) BDNF serum concentrations in healthy humans are associated with depression-related personality traits. Neuropsychopharmacology 29: 795-8. 18) K.-H. Schulz, S.M. Gold, J. Witte, K. Bartsch, U.E. Lang, R. Hellweg, R. Reer, K.-M. Braumann, C. Heesen (2004) Impact of aerobic training on immune-endocrine parameters, neurotrophic factors, quality of life and coordinative function in multiple sclerosis. Neurol Sci 225: 11-8. 19) U.E. Lang, M.C. Jockers-Scherübl, R. Hellweg (2004) Neurotrophins in psychiatric disorders. State of the art: implications and limitations. J Neural Transmission 111: 387-411. 20) U.E. Lang, M. Bajbouj , C. Wernicke, H. Rommelspacher , H. Danker-Hopfe, J. Gallinat (2004) No association of a functional polymorphism in the serotonin transporter gene promoter and anxiety-related personality traits. Neuropsychobiology 49:182-4. 21) M.C. Jockers-Scherubl, H. Danker-Hopfe R. Mahlberg, F. Selig, J. Rentzsch, F. Schurer, U.E. Lang, R. Hellweg (2004) Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse. Neurosci Lett 371: 7983. 22) N. Jeck , S. Waldegger, A. Lampert, C. Boehmer, P. Waldegger, P.A. Lang, B. Wissinger, B. Friedrich, T. Risler, R. Moehle, U.E. Lang, P. Zill, B. Bondy, E. Schaeffeler, S. Asante-Poku, H. Seyberth, M. Schwab, F. Lang (2005) Activating Mutation of the Renal Epithelial Chloride Channel ClC-Kb Predisposing to Hypertension. Hypertension 43: 1175-81. 23) J. Gallinat, D. Kunz, U.E. Lang, G. Juckel, R. Mahlberg, C. Wernicke, H. Rommelspacher, M.N. Smolka (2005) Serotonergic effects of smoking are independent from the human serotonin transporter gene promoter polymorphism: Evidence from auditory cortical stimulus processing. Pharmacopsychiatry 38: 158-160. 24) U.E. Lang, R. Hellweg, J. Gallinat (2005) Association of BDNF serum concentrations with central serotonergic activity: Evidence from auditory signal processing. Neuropsychopharmacology 30: 1148-53. 25) U.E. Lang, R. Hellweg, P. Kalus, M. Bajbouj, K.P. Lenzen, T. Sander, D. Kunz, J. Gallinat (2005) Association of a functional BDNF polymorphism and anxiety-related personality traits. Psychopharmacology 180: 95-9. 26) N. Strutz-Seebohm, G. Seebohm, A. F. Mack, H.-J. Wagner, L. Just, T. Skutella, U.E. Lang, G. Henke, M. Striegel, M. Hollmann, N. Rouach, R.A. Nicoll, J.A. McCormick, J. Wang, D. Pearce F. Lang (2005) Regulation of GluR1 abundance in hippocampal neurons by serum- and glucocorticoid-inducible kinase 3. J Physiology 565: 381-90. 27) C. Sandu, R. Rexhepaj, F. Grahammer, J.A. McCormick, G. Henke, M. Palmada, S. Nammi, U. Lang, M. Metzger, L. Just, T. Skutella, K. Dawson, J. Wang, D. Pearce, F. Lang (2005) Decreased intestinal glucose transport in the sgk3-knockout mouse. Pflugers Arch 51: 437-44. 28) J. Gallinat, R. Hellweg, U.E. Lang (2005) Indicators of Central Serotonergic Activity: How 'Specific' is Neurotransmission? Neuropsychopharmacology 30: 1586-1587. 29) J. Gallinat, A. Ströhle, MD, U.E. Lang, M. Bajbouj, P. Kalus, C. Montag, F. Seifert, C. Wernicke, H. Rommelspacher, H. Rinneberg, F. Schubert (2006) Association of human hippocampal neurochemistry, serotonin transporter genetic variation, and anxiety. Neuroimage 26: 123-31. 30) M. Bajbouj, A. Luborzewski, H. Danker-Hopfe, U.E. Lang (2005) Motor cortical excitability in depressive patients after electroconvulsive therapy and repetitive transcranial magnetic stimulation. J ECT 21: 243-5. 31) T. Müller, U.E. Lang, S. Muhlack, J. Welnic, R. Hellweg (2005) Impact of levodopa on reduced nerve growth factor levels in Parkinson’s disease patients. Clinical Neuropharmacology 28: 238-240. 32) M. Bajbouj, U.E. Lang, P. Neu, I. Heuser (2005) Therapeutic brain stimulation and cortical excitability in depressed patients. Am J Psychiatry 162:2192-3. 33) M. Bajbouj, E.L. Brakemeier, F. Schubert, U.E. Lang, P. Neu, C. Schindowski, H. Danker-Hopfe (2005) Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex and cortical excitability in patients with major depressive disorder. Exp Neurol 196: 332-8. 34) A. Frey, A. Lampert, S. Waldegger, N. Jeck, P. Waldegger, F. Artunc, G. Seebohm, U.E. Lang, S. Kupka, M. Pfister, J. Hoppe, C. Gerloff, E. Schaeffeler, M. Schwab, F. Lang (2006) Influence of gain of function epithelial chloride channel ClC-Kb mutation on hearing thresholds. Hear Res 214:68-75. 35) U.E. Lang, D.P. Wolfer, F. Grahammer, N. Strutz-Seebohm, G. Seebohm, H.-P. Lipp, J.A. McCormick, R. Hellweg, K. Dawson, J. Wang, D. Pearce, F. Lang (2006) Reduced locomotion in the Serum and Glucocorticoid inducible Kinase 3 knock out mouse. Behavioral Brain Research 167:75-86. 36) M. Bajbouj, U.E. Lang, E. Niehaus, F.E. Hellen, I. Heuser, P. Neu (2006) Effects of right unilateral electroconvulsive therapy on motor cortical excitability in depressive patients. J Psychiatr Res 40(4):32237) M. Bajbouj, S.H. Lisanby, U.E. Lang, H. Danker-Hopfe, I. Heuser, P. Neu (2006) Evidence for Impaired Cortical Inhibition in Patients with Unipolar Major Depression. Biol Psychiatry 59(5):395-400. 38) U.E. Lang, M. Bajbouj, J. Gallinat, R. Hellweg. Brain - derived neurotrophic factor serum concentrations in depressive patients during vagus nerve stimulation and repetitive transcranial magnetic stimulation. Psychopharmacology 187: 56-9. 39) J. Kirchheiner, U.E. Lang, T. Stamm, T. Sander, J. Gallinat (2006) Association of CYP2D6 genotypes and personality traits in psychiatric healthy individuals. J Clin Psychiatry 26: 440-2. 40) J. Gallinat*, U.E. Lang*, D. Kunz, P. Neu, N. Kassim, T. Kienast, F. Seifert, F. Schubert, M. Bajbouj (2007) Association between cerebral glutamate and human behaviour: The sensation seeking personality trait. Neuroimage 34: 671-8. 41) U.E. Lang, R. Hellweg (2006) Berufsunfähigkeit: Prävalenz und Rolle psychiatrischer Erkrankungen. Versicherungsmedizin 58: 164-9. 42) M. Domula, D. Schulze, S.M. Tugtekin, W. Felber, U.E. Lang (2007) Cat eye syndrome associated with schizophrenia. Pharmacopsychiatry 40: 38-9. 43) U.E. Lang, T. Sander, F.W. Lohoff, R. Hellweg, M. Bajbouj, J. Gallinat (2007) Association of the met66 allele of brain-derived neurotrophic factor (BDNF) with smoking. Psychopharmacology 190(4):433-9. 44) J. Gallinat, U.E. Lang, L.K. Jacobsen, M. Bajbouj, P. Kalus, D. vonHaebler, F. Seifert, F. Schubert (2007) Abnormal hippocampal neurochemistry in smokers: Evidence from proton magnetic resonance spectroscopy at 3 tesla. Clin Psychopharmacology 27: 80-4. 45) M. Bajbouj, J. Gallinat, U.E. Lang,; F. Hellen, J. Vesper; S.H. Lisanby, ; H. Danker-Hopfe,; P. Neu (2007) Motor cortex excitability after vagus nerve stimulation in major depression. J Clin Psychopharmacology 27:156-9. 46) A. Ziegenhorn, O. Schulte-Herbrüggen, H. Danker-Hopfe, M. Malbranc, H.-D. Hartung, D. Anders, U.E. Lang, E. Steinhagen-Thiessen, R.T. Schaub, R. Hellweg (2006) Serum neurotrophins – a study on the time course and influencing factors in a large old age sample. Neurobiol of Aging 28: 1436-45. 47) U.E. Lang, D. Stogowski, D. Schulze, M. Domula, E. Schmidt, W. Felber (2007) Charles Bonnet Syndrome: Visual hallucinations due to vision loss disappeared during treatment with selective serotonin reuptake inhibitors. J Psychopharmacology 21:553-5. 48) U.E. Lang, R. Hellweg, F Schubert, J. Gallinat (2007) Evidence for a role of BDNF on cortical integrity in the living human brain. Biological Psychiatry 62: 530-5. 49) U.E. Lang, M. Willbring, R. von Golitschek, A. Schmeisser, K. Matschke, S. M. Tugtekin. Clozapineinduced myocarditis after long term treatment: Case presentation and clinical perspectives. J Psychopharmacology (in press) 50) U.E. Lang, M. Bajbouj, T. Sander, J. Gallinat (2007) Association of the functional catecholOmethyltransferase VAL158MET polymorphism with the personality trait of sensation seeking. Neuropsychopharmacology 32: 1950-5. 51) U.E. Lang*, R. Hellweg*, J. Gallinat, M. Bajbouj. Acute prefrontal cortex transcranial magnetic stimulation in healthy volunteers: No effects on brain-derived neurotrophic factor (BDNF) concentrations in serum. J Affective Disorder (in press) 52) U.E. Lang, I. Puls, D. Mueller, Nathalie Strutz-Seebohm, Juergen Gallinat. Molecular Mechanisms of Schizophrenia. Cell Physiol Biochem 20: 687-702 53) A. Frey, A. Lampert, R. Möhle, J. Gallinat, F. Lang, U.E. Lang. Thyrotropin serum concentrations in healthy volunteers are associated with depression-related personality traits. Neuropsychobiology (in press)